Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules
09/12/2025 13:32
Dec 9 (Reuters) - Citius Oncology Inc CTOR.O: CITIUS ONCOLOGY ANNOUNCES $18 MILLION CONCURRENT REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES CITIUS ONCOLOGY INC - PROCEEDS SUPPORT LAUNCH OF LYMPHIR FOR CUTANEOUS T-CELL LYMPHOMA CITIUS ONCOLOGY INC - TO PURCHASE 1,284,404 SHARES OF COMMON STOCK AT $1.09 PER SHARE IN DIRECT OFFERING Source text: ID:nPn7TkLKKa Further company coverage: CTOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules